Skip navigation
Skip navigation

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Duchesne, Gillian M; Woo, Henry H; Bassett, Julie K; Bowe, Steven J; D'Este, Catherine; Frydenberg, Mark; King, Madeleine; Ledwich, Leo; Loblaw, Andrew; Malone, Shawn; Millar, Jeremy; Milne, Roger; Smith, Rosemary G; Spry, Nigel; Stockler, Martin; Syme, Rodney A; Tai, Keen Hun; Turner, Sandra


BACKGROUND: Androgen-deprivation therapy is offered to men with prostate cancer who have a rising prostate-specific antigen after curative therapy (PSA relapse) or who are considered not suitable for curative treatment; however, the optimal timing for its introduction is uncertain. We aimed to assess whether immediate androgen-deprivation therapy improves overall survival compared with delayed therapy. METHODS: In this randomised, multicentre, phase 3, non-blinded trial, we recruited...[Show more]

CollectionsANU Research Publications
Date published: 2016
Type: Journal article
Source: The Lancet Oncology
DOI: 10.1016/S1470-2045(16)00107-8


There are no files associated with this item.

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator